

UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes

Meeting Date: September 8, 2022

Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order	G. Shutzberg	5:01 PM		
A. Minutes from previous meetings	G. Shutzberg	Review of Minutes from June 9, 2022	Minutes reviewed, approved	Yes
A. Introduction - P&T Committee Updates	M. Stinchon	Review of Biosimilars, Definition and Pipeline: Presented program overview of how biosimilars give opportunity to manage specialty classes with more cost-effective alternates, and these products have traditionally been launched at a lower cost than the innovator brands.	Non voting item	Yes
B. Formulary Review - New Drugs	C. Lichtinger	Epsolay		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	C. Lichtinger	Hyftor		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Comment:	Discussion held regarding the prescriber requirements.		
	C. Lichtinger	Ibsrela		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	C. Lichtinger	Igalmi		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	C. Lichtinger	Pyrukynd		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	M. Reisman	Quviviq		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	M. Reisman	Tlando		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	M. Reisman	Twynco		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
B. Formulary Review - New Drugs (cont.)	M. Reisman	Vijoice		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	M. Reisman	Vivjoa		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	M. Reisman	Vonjo		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
C. Formulary Review - PDL Modifications				
	C. Lichtinger	Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Recommendation: • Flovent HFA AG: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • Asmanex Twisthaler: Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • Arnuity Ellipta: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • Qvar Redihaler: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	Comment:	Discussion held regarding rationale as to why Qvar is moving to non-preferred and the plan to minimize strain on our members and providers.		
		Recommendation: • Breo Ellipta AG: Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • DEKAs: Move to preferred with DX2RX across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • Eszopiclone: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • Irbesartan: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • Telmisartan: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • Valsartan: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
C. Formulary Review - PDL Modifications (cont.)	C. Lichtinger	Recommendation: • Invega Hafyera : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • Efavirenz-emtricitabine-tenofovir (generic Atripla) : Move to preferred with DX2RX across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • Estradiol Bi-weekly Transdermal Patches : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • Non-insulin Syringes : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • Lansoprazole ODT (RX formulation) : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
D. Formulary Review - New Drugs-Medical	M. Reisman	Confirm Review of New Drugs- Medical Grid	Yes/No	Yes
		Opdualag		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Carvykti		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Camcevi		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Korsuva		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Prolia		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
E. Formulary Review - Drugs Evaluated Per Grid	M. Reisman	Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	11:0
F. Clinical Guidelines	M. Reisman	Clinical Guideline Review		
		Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	11:0
		Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	11:0
		Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	11:0
G. Quality Monitoring	L. Smith/C. Lichtinger	Confirm Review of Quality Data	Yes/No	Yes
	L. Smith	DUR Review		
	Comment:	Discussion held regarding the adherence program pilot outcomes, including information about understanding barriers to care. Suggestion was made to review these barrier at a later meeting.		
	C. Lichtinger	COVID Dashboard		
	C. Lichtinger	Drug Recalls Q2 2022		
	C. Lichtinger	Top 25 Drugs by Spend and Volume – 2nd Quarter 2022		
	C. Lichtinger	Top 10 Drugs Requested - Approvals and Denials – 2nd Quarter 2022		
	C. Lichtinger	Grievances and Appeals Data – 2nd Quarter 2022		
	C. Lichtinger	Inter-Rater Reliability (IRR) – 2nd Quarter 2022 • Pharmacists		
Adjournment	G. Shutzberg		6:37 PM	
Comments: · Please note that one of our committee members was not able to attend the meeting in its entirety. This in turn is reflected in the total number of voters for a few agenda items.				

Respectfully Submitted to the Committee,



James P. Hancovsky, M.S.I.A., R.Ph.
Chief Pharmacy Officer, UHC C&S